Idiopathic inflammatory myopathies

Czech version

Authors: Jiří Vencovský
Authors‘ workplace: Revmatologický ústav, Praha
Published in: Vnitř Lék 2018; 64(2): 155-163
Category: Reviews

Overview

Idiopathic inflammatory myopathies form a heterogeneous group of acquired inflammatory diseases afflicting striated muscles. The disease is frequently accompanied by systemic and organ involvement. Dermatomyositis, polymyositis, cancer associated myositis, immune mediated necrotizing myopathy, myositis in overlap syndromes, juvenile myositis and inclusion body myositis are the most frequently encountered subtypes. The basic manifestation is usually painless muscle weakness brought about by inflammation and by other immune changes at the impacted muscles. Enzymes of muscle origin and myoglobin are found elevated in the circulation. There are changes in electrical properties of muscle fibers detected by EMG. A majority of patients have autoantibodies against nuclear or cytoplasmic antigens in their serum. They are often very specific for these diseases and frequently found in association with particular clinical presentations. For some patients with dermatomyositis the increased incidence of cancer is significantly associated with anti-TIF1γ and anti-NXP2 autoantibodies. Differential diagnostics of inflammatory myopathies is often difficult. Misdiagnosis for a non-inflammatory myopathy is not rare and therefore a very thorough diagnostic approach is necessary. Therapy aims to suppression of autoimmune response using glucocorticoids and immunosuppressive drugs. In large part of patients the response to standard treatment is not sufficient and less common synthetic compounds, biological drugs or intravenous immunoglobulins need to be used. Most patients with inclusion body myositis has limited or no effect of any treatment.

Key words:
autoantibodies – autoimmunity – inflammation – myopathy – myositis – systemic disease

Sources

1. Vencovský J. Idiopatické zánětlivé myopatie. In: Pavelka K, Vencovský J, Horák P et al (eds). Revmatologie. Maxdorf: Praha 2012: 382–392. ISBN 978–80–7345–295–7.

2. Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015; 372(18): 1734–1747. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra1402225>.

3. Svensson J, Arkema EV, Lundberg IE et al. Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. Rheumatology (Oxford) 2017; 56(5): 802–810. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/kew503>.

4. Barnabe C, Joseph L, Bélisle P et al. Prevalence of autoimmune inflammatory myopathy in the first nations population of Alberta, Canada. Arthritis Care Res (Hoboken) 2012; 64(11): 1715–1719. Dostupné z DOI: <http://dx.doi.org/10.1002/acr.21743>.

5. Tansley S, Gunawardena H. The evolving spectrum of polymyositis and dermatomyositis-moving towards clinicoserological syndromes: a critical review. Clin Rev Allergy Immunol 2014; 47(3): 264–273. Dostupné z DOI: <http://dx.doi.org/10.1007/s12016–013–8387–6>.

6. Miller FW, Cooper RG, Vencovský J et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum 2013; 65(12): 3239–3247. Dostupné z DOI: <http://dx.doi.org/10.1002/art.38137>.

7. Mann H, Vencovský J. Terapie idiopatických zánětlivých myopatií. In: Pavelka K, Vencovský J, Šenolt L et al (eds). Farmakoterapie revmatických onemocnění. Maxdorf: Praha 2017. ISBN 978–80–7345–537–8.

8. Ekholm L, Vosslamber S, Tjärnlund A et al. Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies. Scand J Immunol 2016; 84(2): 100–109. Dostupné z DOI: <http://dx.doi.org/10.1111/sji.12449>.

9. Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med 2016; 374(7): 664–669. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra1515161>.

10. Vencovský J. Muscular manifestations. In: Aggarwal R, Oddis C (eds). Managing myositis: a practical guide. Springer 2017. V tisku.

11. Alexanderson H, Broman L, Tollbäck A et al. Functional index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2006; 55(1): 114–122. Dostupné z DOI: <http://dx.doi.org/10.1002/art.21715>.

12. Vencovský J, Řehák F, Pafko P et al. Acute cricopharyngeal obstruction in dermatomyositis. J Rheumatol 1988; 15(6): 1016–1018.

13. Klein M, Mann H, Pleštilová L et al. Arthritis in idiopathic inflammatory myopathy: clinical features and autoantibody associations. J Rheumatol 2014; 41(6): 1133–1139. Dostupné z DOI: <http://dx.doi.org/10.3899/jrheum.131223>.

14. Tiniakou E, Mammen AL. Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review. Clin Rev Allergy Immunol 2017; 52(1): 20–33. Dostupné z DOI: <http://dx.doi.org/10.1007/s12016–015–8511-x>.

15. Selva-O‘Callaghan A, Trallero-Araguás E, Grau-Junyent JM et al. Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol 2010; 22(6): 627–632. Dostupné z DOI: <http://dx.doi.org/10.1097/BOR.0b013e32833f1075>.

16. Madan V, Chinoy H, Griffiths CE et al. Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol 2009; 34(4): 451–455. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2230.2009.03216.x>.

17. Rose MR. [ENMC IBM Working Group]. 188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 2013; 23(12): 1044–1055. Dostupné z DOI: <http://dx.doi.org/10.1016/j.nmd.2013.08.007.

18. Vencovský J. Imunitně zprostředkovaná nekrotizující myopatie asociovaná s léčbou statiny. Čas Lék Čes 2016; 155(6): 319–323.

19. Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am 2002; 28(4): 779–798.

20. Hoogendijk JE, Amato AA, Lecky BR et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14(5): 337–345. Dostupné z DOI:

21. Tomasová Studýnková J, Charvát F, Jarosová K et al. The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford) 2007; 46(7): 1174–1179. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/kem088>.

22. Kubínová K, Mann H, Vencovský J. MRI scoring methods used in evaluation of muscle involvement in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol 2017; 29(6): 623–631. Dostupné z DOI: <http://dx.doi.org/10.1097/BOR.0000000000000435>.

23. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292(7): 344–347. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM197502132920706>.

24. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292(8): 403–407. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM197502202920807>.

25. Lundberg IE, Tjärnlund A, Bottai M et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017;76(12):1955–1964.

26. Mann HF, Vencovsky J, Lundberg IE. Treatment-resistant inflammatory myopathy. Best Pract Res Clin Rheumatol 2010; 24(3): 427–440. Dostupné z DOI: <http://dx.doi.org/10.1016/j.berh.2009.12.008>.

27. Ruperto N, Pistorio A, Oliveira S et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 2016; 387(10019): 671–678. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)01021–1>.

28. Oddis CV, Reed AM, Aggarwal R et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65(2): 314–324. Dostupné z DOI: <http://dx.doi.org/10.1002/art.37754>.